Phreesia Faces Federal Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Deadline: Phreesia, Inc. reminds investors that July 13, 2026, is the deadline to apply for lead plaintiff status in a federal securities class action, emphasizing the importance of timely action for investor rights protection.
- False Statements Allegation: The lawsuit alleges that Phreesia made materially false and misleading statements from May 8, 2025, to March 30, 2026, concealing the slowing demand and reduced visibility in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, highlighting the company's vulnerabilities in the market.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market concerns and a loss of confidence in the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.920
Low
24.00
Averages
29.09
High
35.00
Current: 8.920
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Set to Announce Q1 Earnings on May 27
- Earnings Announcement: Phreesia (PHR) is set to release its Q1 earnings on May 27 after market close, with consensus EPS estimates at $0.29, reflecting a remarkable 514.3% year-over-year increase, indicating significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $130.07 million, representing a 12.2% year-over-year growth, although the company faces challenges from network solutions and the integration of AccessOne, suggesting potential growth despite headwinds.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, which highlights strong revenue management, although profitability still requires improvement.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 6 downward adjustments, while revenue estimates also saw no upward revisions and 15 downward adjustments, reflecting a lack of confidence in the company's future performance.
See More
Phreesia Faces Federal Securities Class Action
- Lawsuit Deadline: Phreesia, Inc. reminds investors that July 13, 2026, is the deadline to apply for lead plaintiff status in a federal securities class action, emphasizing the importance of timely action for investor rights protection.
- False Statements Allegation: The lawsuit alleges that Phreesia made materially false and misleading statements from May 8, 2025, to March 30, 2026, concealing the slowing demand and reduced visibility in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, highlighting the company's vulnerabilities in the market.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market concerns and a loss of confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Phreesia, alleging securities fraud or other unlawful business practices, with investors having until July 13, 2026, to apply as Lead Plaintiff.
- Revenue Guidance Downgrade: On March 30, 2026, Phreesia revealed significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors such as worsening visibility and weaker pharmaceutical marketing commitments.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating a negative market sentiment regarding the company's future prospects.
- Legal Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience in corporate and securities litigation, dedicated to fighting for the rights of victims of securities fraud and has recovered numerous multimillion-dollar damages for class members.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Phreesia, Inc. (NYSE: PHR) common stock purchasers from May 8, 2025, to March 30, 2026, aiming to provide compensation to investors, reflecting the legal risks and potential financial losses faced by the company.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged, indicating a severe crisis in market trust for the company.
- Investor Action Guidance: Investors can join the lawsuit by visiting the Rosen Law Firm website or calling toll-free at 866-767-3653, emphasizing the proactive role and choice investors have in legal proceedings.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling similar cases.
See More
Commvault Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating claims on behalf of Commvault Systems, Inc. shareholders regarding potential breaches of fiduciary duties by executives, which could lead to significant corporate governance reforms if substantiated.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors through executives' materially false statements, failing to disclose critical variables affecting projected ARR growth for fiscal year 2026, resulting in investor misconceptions about the company's prospects.
- Potential Compensation Opportunities: Shareholders holding Commvault shares can seek the return of funds and a court-approved incentive award at no cost, which may encourage more shareholders to participate in the lawsuit and seek redress.
- Negative Market Reaction: The legal risks and potential financial liabilities facing the company have undermined market confidence in Commvault, likely putting pressure on its stock price and affecting investor decisions and future financing capabilities.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. for stock purchasers between May 8, 2025, and March 30, 2026, indicating potential investor losses during this period.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Lawsuit Allegations: The lawsuit claims that Phreesia made false or misleading statements during the class period, concealing material adverse facts regarding slowing demand and reduced visibility in key revenue streams, which led to investor damages.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered hundreds of millions for investors, showcasing its strong track record and expertise in protecting investor rights.
See More
Phreesia Set to Announce Q1 Earnings on May 27
- Earnings Announcement: Phreesia (PHR) is set to release its Q1 earnings on May 27 after market close, with consensus EPS estimates at $0.29, reflecting a remarkable 514.3% year-over-year increase, indicating significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $130.07 million, representing a 12.2% year-over-year growth, although the company faces challenges from network solutions and the integration of AccessOne, suggesting potential growth despite headwinds.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, which highlights strong revenue management, although profitability still requires improvement.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 6 downward adjustments, while revenue estimates also saw no upward revisions and 15 downward adjustments, reflecting a lack of confidence in the company's future performance.
See More
Phreesia Faces Federal Securities Class Action
- Lawsuit Deadline: Phreesia, Inc. reminds investors that July 13, 2026, is the deadline to apply for lead plaintiff status in a federal securities class action, emphasizing the importance of timely action for investor rights protection.
- False Statements Allegation: The lawsuit alleges that Phreesia made materially false and misleading statements from May 8, 2025, to March 30, 2026, concealing the slowing demand and reduced visibility in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, highlighting the company's vulnerabilities in the market.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market concerns and a loss of confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Phreesia, alleging securities fraud or other unlawful business practices, with investors having until July 13, 2026, to apply as Lead Plaintiff.
- Revenue Guidance Downgrade: On March 30, 2026, Phreesia revealed significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors such as worsening visibility and weaker pharmaceutical marketing commitments.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating a negative market sentiment regarding the company's future prospects.
- Legal Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience in corporate and securities litigation, dedicated to fighting for the rights of victims of securities fraud and has recovered numerous multimillion-dollar damages for class members.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Phreesia, Inc. (NYSE: PHR) common stock purchasers from May 8, 2025, to March 30, 2026, aiming to provide compensation to investors, reflecting the legal risks and potential financial losses faced by the company.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged, indicating a severe crisis in market trust for the company.
- Investor Action Guidance: Investors can join the lawsuit by visiting the Rosen Law Firm website or calling toll-free at 866-767-3653, emphasizing the proactive role and choice investors have in legal proceedings.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling similar cases.
See More
Commvault Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating claims on behalf of Commvault Systems, Inc. shareholders regarding potential breaches of fiduciary duties by executives, which could lead to significant corporate governance reforms if substantiated.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors through executives' materially false statements, failing to disclose critical variables affecting projected ARR growth for fiscal year 2026, resulting in investor misconceptions about the company's prospects.
- Potential Compensation Opportunities: Shareholders holding Commvault shares can seek the return of funds and a court-approved incentive award at no cost, which may encourage more shareholders to participate in the lawsuit and seek redress.
- Negative Market Reaction: The legal risks and potential financial liabilities facing the company have undermined market confidence in Commvault, likely putting pressure on its stock price and affecting investor decisions and future financing capabilities.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. for stock purchasers between May 8, 2025, and March 30, 2026, indicating potential investor losses during this period.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Lawsuit Allegations: The lawsuit claims that Phreesia made false or misleading statements during the class period, concealing material adverse facts regarding slowing demand and reduced visibility in key revenue streams, which led to investor damages.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered hundreds of millions for investors, showcasing its strong track record and expertise in protecting investor rights.
See More
